v3.26.1
Related Parties Transactions - Schedule of Related Parties Transactions (Details) - USD ($)
 6 Months Ended
Jun. 30, 2026
Dec. 31, 2025
BioFirst [Member]    
Schedule of Related Parties Transactions [Line Items]    
Due from related party- Current [1] $ 134,026 $ 761,017
Rgene [Member]    
Schedule of Related Parties Transactions [Line Items]    
Due from related party- Current [2] 2,317 2,347
Director [Member]    
Schedule of Related Parties Transactions [Line Items]    
Due from related party- Current [3] 1 24
Related Party [Member]    
Schedule of Related Parties Transactions [Line Items]    
Due from related party- Current 136,344 763,388
Due from related parties- Non-current, net 963,740 960,193
Less: allowance for expected credit losses accounts (963,740) (960,193)
Net
Due to related parties 265,299 105,704
BioFirst (Australia) [Member]    
Schedule of Related Parties Transactions [Line Items]    
Due from related parties- Non-current, net [4] 839,983 839,983
BioHopeKing Corporation [Member]    
Schedule of Related Parties Transactions [Line Items]    
Due from related parties- Non-current, net [5] 123,757 120,210
The Jiangs [Member]    
Schedule of Related Parties Transactions [Line Items]    
Due to related parties [6] 277 300
Shareholders and Subsidiaries' management [Member]    
Schedule of Related Parties Transactions [Line Items]    
Due to related parties [7] 265,022
ForSeeCon [Member]    
Schedule of Related Parties Transactions [Line Items]    
Due to related parties [8] 70,000
OncoX [Member]    
Schedule of Related Parties Transactions [Line Items]    
Due to related parties [8] $ 35,404
BioFirst Corporation (the "BioFirst") [Member]    
Schedule of Related Parties Transactions [Line Items]    
Relationship with the Company and its subsidiaries Entity controlled by controlling beneficiary shareholder of YuanGene  
BioFirst (Australia) Pty Ltd. (the “BioFirst (Australia)”) [Member]    
Schedule of Related Parties Transactions [Line Items]    
Relationship with the Company and its subsidiaries 100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene  
Rgene Corporation (the “Rgene”) [Member]    
Schedule of Related Parties Transactions [Line Items]    
Relationship with the Company and its subsidiaries Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang  
GenePharm Inc. (the “GenePharm”) [Member]    
Schedule of Related Parties Transactions [Line Items]    
Relationship with the Company and its subsidiaries Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.  
The Jiangs [Member]    
Schedule of Related Parties Transactions [Line Items]    
Relationship with the Company and its subsidiaries Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst   Ms. Shuling Jiang, is the Chairman of Keypoint; and a member of board of directors of the Company and BioLite Inc, and a member of board of directors of BioFirst; a director and beneficial owner of more than 10% of the ABVC’s outstanding common stock   Mr. Eugene Jiang is Mr. and Ms. Jiang’s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. Mr. Eugene Jiang is a member of board of directors of BioFirst.   Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang’s sibling and the director of the Company, and a member of board of directors of BioFirst.   Ms. Mei-Ling Jiang is Ms. Shuling Jiang’s sibling.  
BioLite Japan [Member]    
Schedule of Related Parties Transactions [Line Items]    
Relationship with the Company and its subsidiaries Entity controlled by controlling beneficiary shareholder of ABVC  
BioHopeKing Corporation (“BHK”) [Member]    
Schedule of Related Parties Transactions [Line Items]    
Relationship with the Company and its subsidiaries Entity controlled by controlling beneficiary shareholder of ABVC  
AiBtl (Holding) BioPharma, Inc. (“AiBtl Holding”) [Member]    
Schedule of Related Parties Transactions [Line Items]    
Relationship with the Company and its subsidiaries Founding shareholder of AiBtl BioPharma Inc.  
Jaimes Vargas Russman [Member]    
Schedule of Related Parties Transactions [Line Items]    
Relationship with the Company and its subsidiaries CEO of AiBtl BioPharma Inc.  
Lion Arts Promotion, Inc. (“Lion Arts”) [Member]    
Schedule of Related Parties Transactions [Line Items]    
Relationship with the Company and its subsidiaries Entity controlled by the Jiangs.  
[1]

On December 31, 2023, BioLite Taiwan entered into a loan agreement with BioFirst, with a principal amount of $337,707, which bears interest at 12% per annum for the use of working capital. During the year ended December 31, 2024, the Company entered into another loan agreement with BioFirst, with a principal amount of $347,883, which bears interest at 12% per annum for the use of working capital. During the six months ended June 30, 2026, the Company entered several loan agreements with BioFirst, in the aggregate of $147,572. These loans bear 12% per annum, with the term of 12 months. During the six months ended June 30, 2026, the Company also received around $793,567 repayment. The funds were used to support BioFirst’ daily operations.

 

As of June 30, 2026 and December 31, 2025, the outstanding loan and interest balance were $97,842 and $761,017, respectively.

 

As of June 30, 2026 and December 31, 2025, the Company has other receivables amounted to $36,184 and nil, respectively.
[2] As of June 30, 2026 and December 31, 2025, the Company has other receivables amounted $2,317 and $2,347, respectively, from Rgene due to daily operations.
[3] The director paid certain operating expenses on behalf of the Company.
[4]

On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $361,487 to properly record R&D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to be mature on September 30, 2021 with an interest rate of 6.5% per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873 to meet its new project needs. On July 27, 2021, the Company repaid a loan 249,975 to BioFirst (Australia). On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $250,000 to increase the cost for upcoming projects. The loan will be matured on November 30, 2022 with an interest rate of 6.5% per annum. In 2022, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $507,000 to increase the cost for upcoming projects.  During the first quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $88,091 to increase the cost for upcoming projects. During the second quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $25,500 to increase the cost for upcoming projects. All the loans period was twelve months with an interest rate of 6.5% per annum. For accounting purpose, the due from and due to related party balances was being net off. As of June 30, 2026 and December 31, 2025, the outstanding loan balances and allocated research fee were both amounted to $681,185, and accrued interest balances were both amounted $158,798.

 

The business conditions of BioFirst (Australia) deteriorated and, as a result, the Company recognized expected credit losses of $839,983 for the year ended December 31, 2023. The Company stopped accruing interest income recognizing such losses.
[5] On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the “BHK”) entered into a co-development agreement, (the “BHK Co-Development Agreement”, see Note 4). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of  June 30, 2026 and December 31, 2025, due from BHK was both NTD 3,941,299 (approximately$123,363 and $120,210, respectively). The business conditions of BHK deteriorated and as a result, the Company recognized expected credit losses of NTD 3,941,299 as of December 31, 2024. No recovery was made during the six months ended June 30, 2026.
[6]

Since 2019, the Jiangs advanced funds to the Company for working capital purposes. As of March 31, 2026 and December 31, 2025, the outstanding balance due to the Jiangs amounted to $277 and $300, respectively. These loans bear no interest and are due on demand. In addition, during year ended 2025, the Company purchased a piece of land in Taiwan from Shuling Jiang, as discussed in Note 5.
[7] At the end of June 30, 2026, the shareholders advanced funds to the Company for working capital purposes.The advances bear an interest rate around 12% per annum, starting from July 1, 2026 for a term of one year. In June 2026, management of Biokey advanced funds to Biokey for working capital purposes. The advances does not bear any interest.
[8] As of December 31, 2025, the Company had balances due to ForSeeCon and OncoX of $70,000 and $35,404, respectively, relating to amounts previously received but not recognized as licensing revenue. During the first quarter of 2026, the Company settled the outstanding balances with ForSeeCon and OncoX. Accordingly, no amounts remained payable to either party as of June 30, 2026.